Ostarine

Ostarine is a nonsteroidal selective androgen receptor modulator, a class of compounds abbreviated SARM ^[1][2]. Like anabolic steroids, SARMs act on the androgen receptor, the same receptor that responds to testosterone, but they are designed to do so selectively, producing anabolic (tissue-building) effects in muscle and bone while having weaker effects in tissues such as the prostate ^[2][3]. Ostarine, developed under the code name MK-2866 and the drug name enobosarm, is the most extensively studied compound of its type ^[3].

Enobosarm was developed by the pharmaceutical company GTx and advanced into human trials for the loss of muscle and physical function that accompanies serious illness ^[1][3]. It is taken by mouth and, unlike testosterone, is not converted to estrogen and does not carry the same virilizing profile, which was part of the rationale for developing it as an anabolic agent with a cleaner side-effect profile ^[3].

The main clinical focus for ostarine has been muscle wasting, including cancer cachexia and age-related muscle loss ^[1][2][3]. In a randomized phase 2 trial in patients with cancer, enobosarm increased lean body mass compared with placebo ^[1], and it was carried into large phase 3 trials, the POWER studies, in people with non-small-cell lung cancer ^[3]. Across these programs the drug reliably increased lean mass, but it did not consistently improve measures of physical function such as muscle strength, and development for muscle wasting was ultimately discontinued ^[1][3]. More recently the compound has been studied for androgen receptor-positive breast cancer.

Ostarine is not an approved drug and is not available as a licensed medicine ^[3]. Despite this, it is widely sold through unregulated online channels for muscle building and athletic performance, often at doses well above those used in trials. It has been prohibited in sport by the World Anti-Doping Agency since 2008, and a number of athletes have tested positive for it, in some cases traced to contaminated supplements. Drug regulators have warned that SARMs sold this way carry real risks, including liver injury and effects on hormones and the cardiovascular system, and that the consequences of the high doses used outside clinical trials are not well understood ^[3].

Ostarine (MK-2866) is a selective androgen receptor modulator that suppresses natural testosterone production, lowers HDL cholesterol, and has been linked to elevated liver enzymes and cases of drug-induced liver injury. Despite investigational study it is not an approved drug for any indication, is banned in sport, and products sold as ostarine are frequently mislabeled or contaminated. Long-term cardiovascular and hormonal consequences are not well defined.

Ostarine, developed under the names MK-2866 and enobosarm, emerged from selective androgen receptor modulator research led by James Dalton and Duane Miller, whose work on nonsteroidal androgens at the University of Tennessee was advanced commercially by the Memphis biotechnology company GTx. The goal was to reproduce the muscle- and bone-building effects of testosterone through a tissue-selective molecule that spared the prostate and avoided the liver toxicity and virilization of anabolic steroids.

Enobosarm became the most clinically studied SARM: a randomized, double-blind, placebo-controlled Phase 2 trial published in The Lancet Oncology in 2013 showed significant gains in lean body mass in patients with cancer, and GTx then ran the large Phase 3 POWER trials in muscle wasting associated with non-small-cell lung cancer. Despite this substantial program, ostarine has never been approved as a medicine in any country. It has been prohibited in sport by the World Anti-Doping Agency since 2008, and regulators including the FDA have warned against its sale in bodybuilding and supplement products.

Among selective androgen receptor modulators, ostarine enjoys unusual credibility because it is backed by the deepest clinical dataset in its class, including randomized controlled trials and two Phase 3 programs, a rarity for compounds that circulate in the performance community. In those studies it consistently increased lean body mass with a side-effect profile far milder than traditional androgens, which is the core of its appeal to researchers and athletes seeking muscle gains without full steroidal burden.

Its oral activity and tissue selectivity made it a template for the entire SARM field. That said, the honest picture includes real caveats: strength gains in trials were more variable than lean-mass gains, the drug suppresses natural testosterone and can lower HDL cholesterol, and it is neither approved nor quality-controlled when sold as a research chemical. It also carries genuine regulatory and anti-doping risk, and it has repeatedly turned up as an undeclared adulterant in supplements.